Energy metabolism and DNA repair
NAD+ trial notes from Highlander Peptide
The cell has daily work to do. Human precursor trials begin to ask whether a larger NAD+ supply improves any of it.
NAD+ and cellular maintenance
The argument for NAD+ begins with ordinary cellular work. NAD+ cycles with NADH to carry electrons in energy metabolism, and enzymes also consume it during signaling and DNA repair. The review by Covarrubias and colleagues brings those roles together. NAD+ is a coenzyme rather than a peptide.
I like this starting point because the molecule already has a job. Supplying more of a useful molecule, however, raises a separate experimental question: which function improves, in which tissue, in which people? The 2025 review of human supplementation studies describes consistent blood increases alongside limited clinical efficacy and sparse tissue-specific data. Daily maintenance is a compelling research subject; demonstrating a longer human life would require much more.
NMN and NR in the blood
NMN stands for nicotinamide mononucleotide; NR is nicotinamide riboside. They are precursors from which cells can make NAD+. The NR trial in healthy overweight adults reported whole-blood NAD+ increases of 22%, 51%, and 142% across its dose groups over 8 weeks. Adverse events did not differ significantly from placebo; flushing and LDL elevation were absent in this trial.
In the multicenter NMN trial, 80 healthy middle-aged adults were studied for 60 days. Blood NAD+ rose in the NMN groups, and walking distance and quality-of-life scores improved versus placebo. No safety issues emerged at the studied doses. These trials establish the blood response to oral precursors. The tissue measurements and longer follow-up are where the harder questions begin.
NMN muscle trial
The 10-week NMN trial in prediabetic postmenopausal women improved skeletal-muscle insulin sensitivity. Investigators used a hyperinsulinemic-euglycemic clamp, a controlled way to measure the response to insulin. Body composition and HbA1c did not change.
The muscle result extends the argument beyond a blood measurement. The muscle responded on a functional measure, while other measures stayed put. It narrows the claim in a useful way: this population, this duration and this metabolic outcome. An answer for healthy adults over many years would need its own trial. The finding leaves room for further work without obliging it to carry the entire anti-aging argument.
Sirtuins, PARPs and CD38
Three enzyme families help explain why NAD+ attracts so much attention. Sirtuins use it in regulating proteins and gene expression; PARPs consume it in DNA-damage responses; CD38 consumes it too, and its activity rises with age and inflammation. NAMPT helps recycle nicotinamide into the NAD+ supply. These roles are covered in the cellular-metabolism review.
Age-related NAD+ decline is well described across experimental models. The human-evidence review adds an essential qualification: direct demonstrations of age-related decline in people are limited, and tissue-specific dynamics remain sparsely measured. I suspect the location of the change will matter at least as much as the size of a blood increase. That is a question the available studies leave for further measurement.
IV NAD+ and safety
The controlled human evidence here mainly concerns oral precursors. IV NAD+ has minimal controlled support, and infused NAD+ clears rapidly from plasma. Reported risks include chest discomfort, abdominal cramps, flushing and nausea when infusions run too quickly. FDA also designated a compounded NAD+ injection recall Class I for elevated bacterial endotoxin. Compounded injectable NAD+ requires a prescription following clinical assessment; it has no FDA drug approval.
Borrowing the oral NMN and NR trial results to validate an infusion would be a leap. The route and the administered substance change together. The mechanistic review also describes NAD+'s context-dependent biology: supporting proliferating cells creates a theoretical concern about the metabolism of existing cancers. Human safety cannot be inferred from the usefulness of NAD+ inside a normal cell.
Supplement status and follow-up
NR is marketed as a dietary supplement. FDA has contested NMN's supplement classification because it was investigated as a drug. Oral NAD+ itself is poorly absorbed intact, so the human trial evidence centers on the precursors. Product purity and actual content can vary.
The 8-week NR safety findings and the 60-day NMN findings give useful short-term information in their studied populations. They leave long-term safety and clinical aging outcomes open. The comparison with Epitalon makes more sense when each result retains its substance, population and duration. Sustained function and careful safety follow-up could carry the clinical argument further than another isolated increase in a biomarker.